ATE332693T1 - Pharmazeutische zusammensetzung zur behandlung und vorbeugung von leberzirrhose und leberfibrose - Google Patents

Pharmazeutische zusammensetzung zur behandlung und vorbeugung von leberzirrhose und leberfibrose

Info

Publication number
ATE332693T1
ATE332693T1 AT01910188T AT01910188T ATE332693T1 AT E332693 T1 ATE332693 T1 AT E332693T1 AT 01910188 T AT01910188 T AT 01910188T AT 01910188 T AT01910188 T AT 01910188T AT E332693 T1 ATE332693 T1 AT E332693T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
liver
pharmaceutical composition
cirrhosis
Prior art date
Application number
AT01910188T
Other languages
German (de)
English (en)
Inventor
Sang Geon Kim
Keon Wook Kang
Original Assignee
Sang Geon Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sang Geon Kim filed Critical Sang Geon Kim
Application granted granted Critical
Publication of ATE332693T1 publication Critical patent/ATE332693T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT01910188T 2000-03-02 2001-03-02 Pharmazeutische zusammensetzung zur behandlung und vorbeugung von leberzirrhose und leberfibrose ATE332693T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20000010540 2000-03-02

Publications (1)

Publication Number Publication Date
ATE332693T1 true ATE332693T1 (de) 2006-08-15

Family

ID=36776473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910188T ATE332693T1 (de) 2000-03-02 2001-03-02 Pharmazeutische zusammensetzung zur behandlung und vorbeugung von leberzirrhose und leberfibrose

Country Status (10)

Country Link
EP (1) EP1263435B1 (enExample)
JP (1) JP4226246B2 (enExample)
CN (1) CN1218698C (enExample)
AT (1) ATE332693T1 (enExample)
AU (1) AU2001237768A1 (enExample)
BR (1) BR0108732A (enExample)
DE (1) DE60121426T2 (enExample)
ES (1) ES2267722T3 (enExample)
RU (1) RU2250768C2 (enExample)
WO (1) WO2001064215A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
KR100604261B1 (ko) * 2004-10-11 2006-07-28 재단법인서울대학교산학협력재단 신규4,5,6,7-테트라히드로-[1,2]디티올로[4,3-ｃ]피리딘-3-티온계 화합물
EP1893211B1 (en) * 2005-06-17 2011-09-14 Novartis AG Use of sanglifehrin in hcv
CA2651623A1 (en) 2006-05-11 2007-11-22 Patrick T. Prendergast Compositions and methods for modulating the immune system

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals

Also Published As

Publication number Publication date
JP4226246B2 (ja) 2009-02-18
WO2001064215A1 (en) 2001-09-07
BR0108732A (pt) 2002-12-17
DE60121426D1 (de) 2006-08-24
DE60121426T2 (de) 2007-02-22
CN1407891A (zh) 2003-04-02
RU2250768C2 (ru) 2005-04-27
AU2001237768A1 (en) 2001-09-12
EP1263435A4 (en) 2004-08-11
EP1263435A1 (en) 2002-12-11
JP2004538239A (ja) 2004-12-24
ES2267722T3 (es) 2007-03-16
CN1218698C (zh) 2005-09-14
RU2002126216A (ru) 2004-03-20
EP1263435B1 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
ATE234634T1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
MY129406A (en) Taste masked liquid pharmaceutical compositions
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HUP0302508A3 (en) Pyridazinones and triazinones and their use as active ingredients of pharmaceutical compositions
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
BG106155A (en) Novel derivatives and analogues of galanthamin
DE69919533D1 (de) Proteinhaltige arzneimittel
DE50115451D1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
WO2005065639A3 (en) Novel pharmaceutical compositions
ATE296635T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
ATE332693T1 (de) Pharmazeutische zusammensetzung zur behandlung und vorbeugung von leberzirrhose und leberfibrose
CA2473202A1 (en) Pharmaceutical composition for regeneration of cirrhotic liver
MY141506A (en) Virus therapeutic drug
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
ATE238034T1 (de) Geschmacksmaskierung schlecht schmeckender formulierungen
GEP20043377B (en) Pharmaceutical Complex
DE60107900D1 (de) Pharmazeutische Zusammensetzung und Nahrungsmittel zur Behandlung von Gehirnödem
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties